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Introduction
Cell migration is a multi-step process involving surface
protrusion, substrate attachment at integrin- and actomyosin-
associated focal adhesions, myosin II-based retraction of the
cell body, and substrate detachment (Bretscher, 1996;
Lauffenburger and Horwitz, 1996; Lin and Forscher, 1995).
Cell spreading, the initial step in this process, can be modeled
by plating cells onto fibronectin-coated coverslips (Betapudi et
al., 2006; Cai et al., 2006; Duxbury et al., 2004; Wakatsuki et
al., 2003) and can be approximated as the sum of two forces
(Wylie and Chantler, 2003). The outward force, driven by actin
polymerization, is opposed by a myosin II-driven inward
contractile force associated with F-actin bundling and
remodeling in a transitional zone behind the extending cell
surface (Brown and Bridgman, 2003; Cai et al., 2006; Gupton
and Waterman-Storer, 2006; Medeiros et al., 2006; Wakatsuki
et al., 2003).
Recent work with cells deficient in individual myosin II
isoforms implicates myosin IIB as being primarily responsible
for focal adhesion stabilization during rapid cell surface
extension, whereas myosin IIA is implicated in the contractile
forces that reduce the rate of cell spreading (Betapudi et al.,
2006; Bridgman et al., 2001; Cai et al., 2006; Lo et al., 2004;
Vincente-Manzanares, 2007; Wylie and Chantler, 2003). This
generalization is tempered by cell type-specific differences
both in myosin II isoforms and in myosin II-binding regulatory
proteins (Bao et al., 2005; Betapudi et al., 2006; Cai et al.,
2006; Simerly et al., 1998; Togo and Steinhardt, 2004). The
fact that some cells contain only one nonmuscle myosin
isoform [e.g. COS7 cells contain only myosin IIB (Betapudi et
al., 2006)] indicates a large degree of functional redundancy
among myosin II isoforms.
Myosin II activation is regulated by monophosphorylation
of its regulatory 20 kDa light chain (myosin light chain, MLC)
on serine-19 and diphosphorylation at a second residue,
threonine-18 (Ikebe, 1989). Diphosphorylation also
differentially stabilizes the extended, filamentous
conformation of myosin (Ikebe et al., 1988; Matsumura, 2005;
Watanabe et al., 2007). Many kinases can phosphorylate and
activate MLC, with Rho kinase and MLC kinase (MLCK)
among the chief regulators (Matsumura, 2005; Murthy, 2006).
These enzymes mediate both mono- and di-phosphorylation of
MLC (Choi et al., 1994; Ikebe, 1989; Itoh et al., 1992; Ueda
et al., 2002). Rho kinase regulates MLC phosphorylation in the
cell interior (Totsukawa et al., 2004) and controls the
development of traction forces in adhesive fibroblasts (Beningo
et al., 2006), perhaps via selective modulation of myosin IIB
(Sandquist et al., 2006), but is not a major contributor during
cell spreading (Betapudi et al., 2006; Totsukawa et al., 2004).
MLCK promotes MLC phosphorylation in the cell periphery
and along stress fibers (Chew et al., 2002; Totsukawa et al.,
2004). MLCK also preferentially co-localizes with myosin IIA
(Blue et al., 2002) and regulates integrin-dependent cell
survival (Connell and Helfman, 2006; Fazal et al., 2005),
perhaps via a signaling cascade downstream of Ras and MEK
(Nguyen et al., 1999). This model is consistent with the
During cell migration, myosin II modulates adhesion, cell
protrusion and actin organization at the leading edge.
We show that an F-actin- and membrane-associated
scaffolding protein, called supervillin (SV, p205), binds
directly to the subfragment 2 domains of nonmuscle myosin
IIA and myosin IIB and to the N-terminus of the long form
of myosin light chain kinase (L-MLCK). SV inhibits cell
spreading via an MLCK- and myosin II-dependent
mechanism. Overexpression of SV reduces the rate of cell
spreading, and RNAi-mediated knockdown of endogenous
SV increases it. Endogenous and EGFP-tagged SV co-
localize with, and enhance the formation of, cortical
bundles of F-actin and activated myosin II during early cell
spreading. The effects of SV are reversed by inhibition of
myosin heavy chain (MHC) ATPase (blebbistatin), MLCK
(ML-7) or MEK (U0126), but not by inhibiting Rho-kinase
with Y-27632. Flag-tagged L-MLCK co-localizes in cortical
bundles with EGFP-SV, and kinase-dead L-MLCK
disorganizes these bundles. The L-MLCK- and myosin-
binding site in SV, SV1-171, rearranges and co-localizes
with mono- and di-phosphorylated myosin light chain and
with L-MLCK, but not with the short form of MLCK (S-
MLCK) or with myosin phosphatase. Thus, the membrane
protein SV apparently contributes to myosin II assembly
during cell spreading by modulating myosin II regulation
by L-MLCK.
Supplementary material available online at
http://jcs.biologists.org/cgi/content/full/120/21/3792/DC1
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3793Supervillin, myosin II and cell spreading
requirement for the kinase activities of MLCK and
extracellular signal-regulated kinase (ERK, also called
MAPK), both of which are downstream of MEK during focal
adhesion disassembly (Webb et al., 2004).
Negative regulation of MLC phosphorylation in nonmuscle
cells is mostly mediated by a tripartite myosin phosphatase
comprised of a ~130 kDa targeting subunit called MYPT1, a
~38 kDa catalytic subunit and a ~20 kDa subunit (reviewed in
Matsumura, 2005; Murthy, 2006). MYPT1 binds to the myosin
S2 subfragment, bringing the catalytic phosphatase into
proximity with MLC (Johnson et al., 1997). Several of the
kinases that promote MLC activation simultaneously
phosphorylate and downregulate myosin phosphatase activity
(Ito et al., 2004; Matsumura, 2005).
We have identified a plasma membrane-associated
cytoskeletal fraction that contains myosin II, F-actin and
signaling proteins in association with a tightly bound
peripheral membrane protein called supervillin (SV, p205)
(Nebl et al., 2002; Pestonjamasp et al., 1997). Over 95% of SV
in differentiated cells localizes and co-fractionates with plasma
membranes (Nebl et al., 2002; Oh et al., 2003; Pestonjamasp
et al., 1997; Wulfkuhle et al., 1999). SV also co-isolates as part
of a cytoskeletal complex with 2-integrin, receptor protein
tyrosine phosphatase  and the P2X7 ATP-gated ion channel,
which regulates cell growth, apoptosis and membrane blebbing
(Kim et al., 2001). SV negatively regulates cell-substrate
adhesion through interactions with the LIM domains of thyroid
receptor-interacting protein 6 (TRIP6) and lipoma-preferred
partner (LPP) (Takizawa et al., 2006). Alternatively spliced
forms of SV found in striated and smooth muscle are involved
in the organization of muscle costameres, stimulus-mediated
contractility of smooth muscle and myogenic differentiation
(Gangopadhyay et al., 2004; Oh et al., 2003). Thus, SV
apparently helps transmit signals across the plasma membrane
to the actin- and myosin II-associated cortex.
A role for SV in regulating membrane-associated
cytoskeletal assembly is supported by direct binding to both
myosin II and F-actin (Chen et al., 2003). The first 171 amino
acids in SV (SV1-171) bind to the S2 regulatory domains of
nonmuscle and smooth muscle myosin II heavy chains. SV
sequences containing combinations of two of the three F-actin-
binding sites within the SV N-terminus (SV amino acids ~280-
342, ~344-422 and ~700-830) also bundle or crosslink actin
filaments in vitro (Chen et al., 2003). The TRIP6- and LPP-
binding site lies within SV amino acids 342-571 (Takizawa et
al., 2006), and the SV C-terminus (SV1542-1792) binds to
calponin (Gangopadhyay et al., 2004), which also binds both
actin and myosin II and regulates their interaction (El-
Mezgueldi and Marston, 1996; Lin et al., 1993). Thus, direct
or indirect sites of interaction with actin and myosin II are
distributed throughout the SV sequence.
We therefore hypothesize that SV is part of a signaling
scaffold that organizes and regulates actin and myosin II
filaments at the membrane. In addition to mediating focal
adhesion turnover via interactions involving TRIP6 in the
center of the cell (Takizawa et al., 2006), we hypothesize that
SV modulation of myosin II activity regulates the rate of cell
spreading. We show here that SV does modulate cell spreading,
apparently by promoting or stabilizing contractile assemblages
of actin and myosin II with the long form of MLCK (L-
MLCK).
Results
Supervillin inversely regulates cell spreading and
associates with peripheral myosin bundles
SV negatively regulates cell spreading on fibronectin (Fig. 1,
supplementary material Fig. S1). In populations of COS7 cells
spreading onto fibronectin, we noticed that cells expressing
EGFP-SV were less well spread than nontransfected cells at
30-45 minutes after plating; no such difference was apparent
for cells expressing EGFP only. Initial spreading was
essentially complete by 60 minutes for all cells. Defining a
‘spread’ cell as one exhibiting a radius greater than twice that
exhibited by the average initially rounded cell (Fig. 1A, panel
a), we quantified the number of spread cells as a function of
time after plating (Fig. 1B). COS7 cells expressing an average
~5-fold excess of EGFP-SV (Takizawa et al., 2006) were
Fig. 1. Overexpressed supervillin decreases the rate of cell spreading.
(A) Quantification of spreading and spread cells. As compared with
the diameter of rounded cells (a), ‘spreading cells’ (b) are smaller
than twice the diameter of the average rounded COS7 cell, which is
23.0±0.7 m (means±s.e.m., n=17), and ‘spread cells’ (c) are larger
than twice the diameter of rounded cells. Bar, 46 m. (B) Percentage
of spread COS7 cells after plating onto 10 g/ml fibronectin for 15,
30, 45, 60 or 90 minutes. Results for control nontransfected cells or
cells expressing EGFP alone or EGFP-SV were obtained.
Means±s.e.m. of 100 cells counted per experiment, n=6. Sample
images are shown in supplementary material Fig. S1. (C) Histogram
of the percentages of spread COS7 cells at 30 minutes after plating
on 10 g/ml fibronectin. Means±s.e.m.; n=6; ***P<0.001 for EGFP-
SV versus both control and EGFP-expressing cells.
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significantly less likely to be spread at 30 minutes, as compared
with control cells or cells expressing EGFP alone (Fig. 1C).
This result was reminiscent of our previous observations of SV-
mediated inhibition of cell-substrate adhesion (Takizawa et al.,
2006).
During early cell spreading, EGFP-SV and myosin heavy
chain (MHC) IIB prominently co-localized in bundles at the
cell periphery, in addition to their abundant signals in the cell
interior (Fig. 2A, panels a-c). EGFP by itself did not co-
localize with myosin bundles after 30 minutes of spreading
(Fig. 2A, panels d-f). Indeed, the circumferential myosin
bundles were far less prominent in untransfected cells (not
shown) or cells expressing only EGFP at this time than in cells
with EGFP-SV (Fig. 2A, panel e versus panel b). By 60
minutes of spreading, peripheral and interior bundles of
myosin were observed in all three types of cells (Fig. 2B and
not shown).
Peripheral bundles of F-actin, activated myosin II and
endogenous SV also formed during spreading of A549 human
lung carcinoma cells (Fig. 3). These cells spread onto
fibronectin with a time course similar to that of COS7 cells
(see below). Consistent with previous reports (Cai et al., 2006;
LoRusso et al., 1997; Sumoza-Toledo et al., 2006), we found
that both MHC IIA and MHC IIB isoforms localize with F-
Journal of Cell Science 120 (21)
actin in peripheral bundles during cell spreading, although
MHC IIA staining was more prominent in A549 cells (Fig. 3a-
f). These bundles were associated with vinculin-stained focal
adhesions (Fig. 3f) and with singly and doubly phosphorylated
MLC (Fig. 3g,h,j), indicating local myosin activation and the
potential for contractility. Immunostained endogenous SV at
the cell periphery overlapped with activated myosin II,
although fainter overlaps of SV with F-actin in myosin-
depleted lamellipodia also were seen (Fig. 3j-r). Thus, although
it contains at least three binding sites for F-actin and only one
for MHC II (Chen et al., 2003), SV might preferentially co-
localize with myosin II during cell spreading.
To determine whether SV binds preferentially to nonmuscle
MHC IIA versus MHC IIB, we analyzed the binding of 6His-
tagged recombinant S2 domains from these myosins to
columns containing GST-tagged SV amino acids 1-174 (GST-
Fig. 2. EGFP-supervillin (EGFP-SV) and myosin heavy chain
(MHC) IIB co-localize at the cell periphery during spreading. 
(A,B) COS7 cells expressing EGFP-SV (upper panels) or EGFP only
(lower panels) after 30 (A) or 60 (B) minutes of spreading were
counterstained with anti-MHC IIB antibodies. EGFP signals (a,d;
green in c,f) and MHC IIB signals visualized in the red channel (b,e;
red in c,f) were merged (c,f); signal overlaps are shown in yellow.
Arrows indicate peripheral co-localizations. Bar, 20 m.
Fig. 3. Co-localization of endogenous proteins during cell spreading.
After 30 minutes of spreading on 10 g/ml fibronectin, A549 cells
were stained with antibodies against MHC IIA (a), tubulin (c), MHC
IIB (d), vinculin (f), mono-phosphorylated serine-19 in MLC (pS19-
MLC; g,j,m), di-phosphorylated threonine-18, serine-19 in MLC
(pT18pS19-MLC; h), or supervillin (k,n) and with Alexa-Fluor-350-
conjugated phalloidin for visualizing F-actin (b,e,i,l,o). Alexa-Fluor-
488-conjugated (a,d,h,k) and Alexa-Fluor-594-conjugated (c,f,g,j)
secondary antibodies were used. (m-o) Enlargements of the boxed
areas in j-l. (p-r) Cross-sections of signal intensities along the
vertical lines in m-o, respectively. Bars, 10 m.
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SV1-174, Fig. 4). These residues contain the binding site of
SV for the smooth muscle myosin S2 domain (Chen et al.,
2003). The S2 domains from both nonmuscle myosin isoforms
bind to GST-SV1-174 (Fig. 4, left column), but not to GST
lacking SV sequences (Fig. 4, right column). Although much
less MHC IIB than MHC IIA S2 domain is eluted by
physiological levels of salt (Fig. 4, left, lanes 2-4), significant
amounts of both myosin isoforms resist extraction with even
0.3 M NaCl, eluting only when GST-SV1-174 is removed from
the column (Fig. 4, left, lane 7). As reported previously (Chen
et al., 2003), no detectable binding of SV to skeletal muscle
myosin II could be observed. Thus, SV can interact with both
nonmuscle myosin IIA and nonmuscle myosin IIB isoforms,
although associations with myosin IIB might be somewhat
stronger.
As expected if endogenous SV plays a role during cell
spreading, we found that reduction of SV levels in A549 cells
using two different dsRNAs increased the rate of spreading
(Fig. 5). Targeting of human SV coding nucleotides 1680-1704
or 2026-2050 with two rounds of dsRNA transfection over 4
days reduced the levels of SV to 10% of normal amounts
without affecting the levels of other proteins analyzed in this
study (Fig. 5A). In both live-cell imaging (Fig. 5B;
supplementary material Movies 1, 2) and counts of spread cells
(Fig. 5C), A549 cells with reduced amounts of SV spread faster
than either mock-transfected cells or cells treated with a control
dsRNA. As with COS7 cells, the largest difference in cell
spreading was observed at 30 minutes, when cells treated with
either dsRNA against SV were significantly more likely to be
spread than cells with normal levels of endogenous protein
(Fig. 5D).
During spreading, reduction of endogenous SV also reduces
the extent of peripheral bundles (Fig. 6), defined as arrays of
concentrated actin and myosin II at the cell edge or at the base
of a lamellipodium (Small et al., 1999). After 30 minutes of
Fig. 4. Supervillin binds to the S2 domains of both of the nonmuscle
myosins – myosin IIA and myosin IIB. GST-tagged SV1-174 (left)
or GST only (right) were pre-bound to glutathione-agarose beads and
incubated with the hexa-histidine (6His)-tagged recombinant S2
domain from the heavy chain of nonmuscle myosin IIA (S2-MHC
IIA), nonmuscle myosin IIB (S2-MHC II) or skeletal muscle myosin
II (S2-Sk-MHC II). Samples (15 l) of void volumes (V, lanes 1),
washes with binding buffer (W, lanes 2), washes with the indicated
concentrations of NaCl in binding buffer (lanes 3-6) and eluates with
5 mM glutathione (E, lanes 7) were analyzed on immunoblots
stained with anti-GST antibodies (top panels) or anti-6His
antibodies (lower panels).
Fig. 5. Supervillin knockdown increases the rate of cell spreading.
(A) Immunoblots of endogenous SV, MHC IIA, MHC IIB, long and
short isoforms of MLCK (L-MLCK and S-MLCK), and ERK1/2, in
lysates from cells treated with transfection reagent alone (lanes 1;
Mock), dsRNAs 1680 (hSV1) or 2026 (hSV2) that target SV (lanes 2,
3), or control dsRNAs (lanes 4, Con). (B) Histogram showing the rates
of area change for populations of A549 cells treated with control (white)
or hSV1 (black) dsRNAs spreading on 10 g/ml fibronectin. Spreading
velocities in the bimodal distributions typical of unsynchronized cells
(Dubin-Thaler et al., 2004) appear to be displaced, but the difference
between the means (36.2±5.7 m2/minute for controls; 51.7±11.3
m2/minute for hSV1) is not statistically significant for the numbers of
living cells (n=16; n=17) assayed. Movies 1 and 2 in the supplementary
material show cell morphologies during linear spreading for average
control- and hSV1-treated cells. (C) Percentage of spread A549 cells
after plating onto 10 g/ml fibronectin at 15, 30, 45, 60 or 90 minutes.
Spread cells were defined as in Fig. 1; the average diameter of a rounded
A549 cell was taken as 18.0±0.8 m (means±s.e.m., n=18). Cells were
mock-transfected, or were treated with hSV1, hSV2 or control dsRNA.
Means±s.e.m. of 200 cells counted per experiment, n=5. (D) Percentage
of spread A549 cells plated on 10 g/ml fibronectin for 30 minutes.
Means±s.e.m.; n=5; *P<0.05 for each SV dsRNA versus both mock and
control dsRNA treatments.
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spreading onto fibronectin, only ~18% (n=200) of A549 cells
treated with a dsRNA against SV contained well-defined
peripheral bundles of myosin and actin, whereas 43% (n=200)
of cells treated with a control or no dsRNA contained these
structures (Fig. 6A). Activated myosin II filaments were still
detectable with antibodies against mono- or doubly-
phosphorylated MLC, but these structures were more widely
distributed throughout the cell cortex (Fig. 6B). Thus, reduced
numbers of peripheral bundles of myosin II and F-actin
accompany SV-mediated reductions in the rate of cell
spreading.
Mediation via MLCK
To explore the mechanism of SV action during cell spreading,
we first treated A549 cells, which contain endogenous SV, with
inhibitors of myosin II function (Fig. 7). We found that the rate
of cell spreading was increased by blebbistatin, which directly
inhibits myosin II ATPase activity (Kovacs et al., 2004;
Limouze et al., 2004; Straight et al., 2003); by ML-7 at a
concentration (1 M) that specifically inhibits MLCK (Bain et
al., 2003); and by the drug U0126, an indirect inhibitor of
MLCK via the upstream kinase MEK (Fincham et al., 2000;
Nguyen et al., 1999). By contrast, Y-27632, which inhibits
direct and indirect activation of myosin by Rho kinase (Amano
et al., 1996; Kimura et al., 1996; Uehata et al., 1997), showed
no significant effect (Fig. 7).
The formation of circumferential bundles of myosin II and
F-actin during spreading of either A549 cells (Fig. 8) or COS7
cells (supplementary material Fig. S2) was inhibited by
blebbistatin (20 M, not shown) or by low concentrations (1
M) of ML-7. As with SV knockdowns, these drugs reduced
the percentage of A549 cells with peripheral bundles after 30
minutes of spreading, from ~40% to ~10% (n=200). The effect
appeared to be selective for peripheral bundles because
cytoplasmic myosin II punctae and filaments remained in each
cell line treated with 1 M ML-7. Reduced numbers of
peripheral bundles of myosin II and F-actin were also observed
after indirect inhibition of myosin II activity with U0126
(2.5 M); inhibition of Rho kinase with Y-27632 was without
effect (supplementary material Fig. S2). ML-7 and U0126
also virtually eliminated the peripheral localization of
phosphorylated MLC (i.e. activated myosin II) (supplementary
material Fig. S3). Taken together, these results suggest that
MLCK might mediate the effects of SV on the rate of cell
spreading and on the formation of peripheral myosin and actin
bundles.
The effects of the myosin II inhibitors on SV-mediated
changes in cell spreading varied with concentration of
blebbistatin and ML-7 (Fig. 9, supplementary material Fig.
S4). Low amounts of blebbistatin (20 M) and ML-7 (1 M)
abolished SV inhibition of COS7 cell spreading, whereas
higher drug concentrations could themselves slow the rate of
spreading (Fig. 9A,B), as described previously (Betapudi et al.,
2006; Duxbury et al., 2004; Jurado et al., 2005). Slowed
spreading at 10 M ML-7 was associated with the disruption
of myosin II filaments, of F-actin bundles and of focal
adhesions throughout the cell (supplementary material Fig.
S4), consistent with the inhibition of all cytoplasmic MLCK
and/or inhibition of another myosin II kinase at higher ML-7
concentrations (Komatsu and Ikebe, 2004). By contrast, the
inhibitory effects of the MEK inhibitor U0126 (Fig. 9C) and
Journal of Cell Science 120 (21)
Fig. 7. Inhibition of myosin ATPase activity directly or via MLCK,
but not via Rho kinase, increases the rate of A549 cell spreading.
Histogram showing the percentage of spread A549 cells plated for 30
minutes on fibronectin in the absence (Control) and presence of
specific inhibitors of: myosin II ATPase (blebbistatin, 20 M),
MLCK (ML-7, 1 M), the MLCK activator MEK (U0126, 2.5 M)
or Rho kinase (Y-27632, 20 M). Means±s.e.m.; 200
cells/experiment, n=6; **P<0.01 versus control.
Fig. 6. Supervillin knockdown decreases the number of peripheral
bundles of MHC IIB and disorganizes the peripheral localization of
phosphorylated MLC. (A) Localization of F-actin (a,d; green in c,f)
and MHC IIB (b,e; red in c,f) in A549 cells treated with hSV1 (a-c)
or control (d-f) dsRNAs after spreading on fibronectin for 30
minutes. (B) Localization of activated MLC using antibodies against
mono-phosphorylated serine-19 (pS19-MLC; a,d), di-phosphorylated
threonine-18, serine-19 (pT18pS19-MLC; b,e) and F-actin visualized
with Alexa-Fluor-350-phalloidin (c,f). Cells were treated with hSV2
dsRNA (a-c) or were mock-treated (d-f) before spreading on
fibronectin for 30 minutes. Signals were visualized in the red (a,d)
and green (b,e) channels. Arrows, peripheral bundles. Bars, 10 m.
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the absence of an effect of the Rho kinase inhibitor Y-27632
(Fig. 9D) were observed at all concentrations tested. These
results suggest that SV might be slowing the rate of cell
spreading by facilitating localized myosin II activation by
MLCK.
To test the possibility of crosstalk between SV and MLCK,
we co-transfected COS7 cells with plasmids encoding EGFP-
SV and Flag-tagged long and short isoforms of MLCK (L-
MLCK, S-MLCK; Fig. 10) (Blue et al., 2002; Herring et al.,
2000). Murine L-MLCK contains the entire S-MLCK coding
sequence. In addition, L-MLCK contains an extra N-terminal
sequence of 954 amino acids with multiple actin-binding sites
within its immunoglobulin (Ig) domains and two DXR repeats
(repeats of a motif made up of the sequence DXRXXL)
(Kudryashov et al., 2004; Poperechnaya et al., 2000; Smith et
al., 2002; Stull et al., 1998; Yang et al., 2006). The shared S-
MLCK C-terminus contains another three DXR repeats, the
kinase domain and a myosin II-binding site (Fig. 11A). A
lysine-to-alanine mutation in the kinase domain generates
kinase-dead (KD) MLCK mutants that inhibit the catalytic
activity of MLCK (Wadgaonkar et al., 2003).
KD mutants of L-MLCK and S-MLCK and the wild-type
forms all co-localized with EGFP-SV in peripheral myosin II
and F-actin bundles during cell spreading (Fig. 10A). Co-
localization was more pronounced for the L-MLCK proteins
(Fig. 10A, panels a-h) than for the S-MLCK proteins (Fig.
10A, panels i-p) because of the high proportion of cytoplasmic
S-MLCK (Blue et al., 2002; Poperechnaya et al., 2000).
To determine whether the SV-mediated effects on cell
spreading require the unique L-MLCK N-terminus, we
determined the rates of spreading for COS7 cells co-transfected
with each MLCK construct and either EGFP-SV or EGFP (Fig.
10B). Either wild-type L-MLCK or S-MLCK, when co-
expressed with EGFP (Fig. 10B, columns 3, 7), mimicked
EGFP-SV (Fig. 10B, column 2) in reducing the initial rates of
Fig. 9. At low concentrations, specific inhibitors of
myosin II activity abolish supervillin-mediated
decreases in spreading of COS7 cells. Percentages of
spread COS7 cells expressing either EGFP-SV or EGFP
at 30 minutes after plating on fibronectin in the presence
of inhibitors of myosin function: (A) MHC ATPase
inhibitor, blebbistatin, **P=0.003 (20 M versus 0 M
for EGFP-SV); (B) MLCK inhibitor, ML-7, **P=0.002
(1.0 M versus 0 M for EGFP-SV); (C) MEK
inhibitor, U0126, *P=0.014 (2.5 M versus 0 M for
EGFP-SV); (D) Rho kinase inhibitor, Y-27632, no
significant effects. Means±s.e.m.; 100 cells per data
point per experiment, n=4.
Fig. 8. Inhibition of MLCK mimics the effect of supervillin
knockdown on the formation of peripheral bundles of activated
myosin during spreading of A549 cells. A549 cells treated with 1
M ML-7 to specifically inhibit MLCK (a-i) lack the peripheral
bundles of activated myosin filaments found in control cells (j-l) after
30 minutes of spreading. Primary antibody staining for MHC IIA (a),
vinculin (c,f), MHC IIB (d), pSer19-MLC (g,j) and pThr18pSer19-
MLC (h,k) was visualized in the green (a,d,h,j) and red (c,f,g,k)
channels. F-actin was visualized with Alexa-Fluor-350–phalloidin
(b,e,i,l). Bar, 10 m.
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cell spreading (column 1). Co-expression of either wild-type
MLCK isoform with EGFP-SV accentuated SV-mediated
reductions in the rate of cell spreading (Fig. 10B, columns 4
and 8 versus column 2). As shown in Fig. 10B, KD L-MLCK
(columns 5, 6) was less effective than wild-type L-MLCK
(columns 3, 4) at reducing spreading rates for EGFP-
expressing cells (column 1) and did not accentuate the effects
of EGFP-SV (column 2). By contrast, KD S-MLCK (columns
9, 10) exhibited an effect similar to that of wild-type S-MLCK
(columns 7, 8). Neither effect was significantly altered by the
Fig. 10. MLCK isoforms, especially L-MLCK, co-localize with
supervillin, and mimic and potentiate supervillin-mediated
decreases in the rates of cell spreading. (A) Fluorescence
micrographs of co-transfected COS7 cells after spreading on
fibronectin for 30 minutes, showing Flag-tagged MLCK proteins, as
indicated (a,e,i,m; red in merged images), EGFP-SV (b,f,j,n; green
in merges) and merged images (c,g,k,o; overlap in yellow). MLCK
proteins were visualized with anti-Flag antibodies and Alexa-Fluor-
594-conjugated anti-rabbit IgG antibodies; F-actin (d,h,l,p) was
visualized with Alexa-Fluor-350–phalloidin. Bar, 20 m. 
(B) Percentages of spread cells 30 minutes after plating on
fibronectin for cells expressing: (1) EGFP only (n=14); (2) EGFP-
SV only (n=14); (3) EGFP plus wild-type (Wt) L-MLCK (n=6); (4)
EGFP-SV plus wild-type L-MLCK (n=9); (5) EGFP plus L-MLCK
KD (n=6); (6) EGFP-SV plus L-MLCK KD (n=9); (7) EGFP plus
wild-type S-MLCK (n=6); (8) EGFP-SV plus wild-type S-MLCK
(n=9); (9) EGFP-SV plus S-MLCK KD (n=6); or (10) EGFP-SV
plus S-MLCK KD (n=9). Means±s.e.m.; 100 cells per experiment;
***P<0.001, **P<0.01. Statistical differences were evaluated using
Student-Newman-Keuls multiple comparisons test. Notice that the x
axis starts at 20%.
Fig. 11. L-MLCK N-terminal sequences reduce the rate of cell
spreading and bind the SV N-terminus. (A) Diagram of L-MLCK, S-
MLCK and mutants. Catalytic core (dark gray); immunoglobulin-like
domains (Ig, stippled); Asp-X-Lysine sequences (DXR, black); and
location (*) of the kinase-inactivating (KD) point mutation are
shown. (B) EGFP-tagged fusion proteins containing N-terminal L-
MLCK sequences (Poperechnaya et al., 2000) reduce the rate of cell
spreading. N-terminal sequences unique to L-MLCK without (Ig) or
with (Ig+5DXRs) all five of the DXRXXL actin-binding motifs
reduce the rate of spreading by ~50%; the 5DXR motifs alone slow
cell spreading by ~30%. Histogram of the percentages of spread
COS7 cells transfected for 16 hours with EGFP as a control or
EGFP-tagged avian L-MLCK sequences, as indicated.
Means±s.e.m.; 100 cells/experiment, n=6; *P<0.05; ***P<0.001
versus EGFP-only control. (C) The L-MLCK Ig domains, but not the
5DXRs, bind directly to SV1-174. GST-tagged SV1-174 (lanes 1-6)
or GST only (lanes 7-12) were pre-bound to glutathione-agarose
beads and incubated with purified recombinant 6His-tagged Ig
domains (upper panel) or 6His-tagged 5DXRs (lower panel). Void
volumes (V, lanes 1, 12), washes with the indicated concentrations of
NaCl (lanes 2-5, 8-11) and glutathione eluates (E, lanes 6,7) were
analyzed on immunoblots stained with anti-6His antibodies.
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presence of EGFP-SV (columns 7 versus 8; 9 versus 10),
implying a kinase- and SV-independent mechanism. The
differences between the effects of KD L-MLCK and KD S-
MLCK (columns 9 versus 5; 10 versus 6) suggest an additional
kinase-independent effect associated with the unique L-MLCK
N-terminus. Thus, these results are consistent with
involvement of SV in an L-MLCK-mediated kinase-dependent
mechanism and with one or more kinase-independent effects
in the rate of cell spreading induced by S-MLCK (the L-MLCK
C-terminus) and by L-MLCK N-terminal sequences.
Multiple mechanisms are supported by domain-mapping
studies of L-MLCK and EGFP-tagged SV sequences (Figs 11,
12). Consistent with a kinase-independent mechanism, L-
MLCK-specific N-terminal sequences (Fig. 11A), which lack
the myosin-binding and kinase domains (Stull et al., 1998) but
bundle actin filaments (Smith et al., 2002; Yang et al., 2006),
slowed the rate of cell spreading by 30-53% (Fig. 11B). A
~26% reduction was also observed with the SV fragments that
can bundle F-actin (Chen et al., 2003), SV343-830 and SV171-
1792 (Fig. 12A).
However, F-actin bundling cannot be the sole mechanism
by which SV reduces the rate of cell spreading. The N-
terminal 171 residues in SV (SV1-171), which do not bind F-
actin but do bind to myosin II (Chen et al., 2003) and to the
L-MLCK N-terminal Ig domains (Fig. 11C), also slowed cell
spreading (Fig. 12A). In addition, EGFP-tagged SV1-171
induces the formation of myosin punctae (Chen et al., 2003)
that co-localize with mono- and di-phosphorylated MLC (Fig.
12B) and with L-MLCK (Fig. 12C, panels a-c). S-MLCK was
far less efficiently associated (Fig. 12C, panels g-i), and these
structures appeared to actually exclude the myosin
phosphatase subunit MYPT1 (Fig. 12C, panels j-l). Time-
lapse imaging of EGFP–SV1-171 showed that the elongated
punctae arise from apparently hypercontractile segments of
stress fibers (supplementary material Movie 3). Taken
together, these results suggest that F-actin bundling is
responsible for at least some of the kinase-independent
reductions in cell spreading and implicate SV1-171 in a
kinase-dependent mechanism involving myosin II activation
by L-MLCK.
Fig. 12. Both F-actin-bundling and myosin II-binding sequences in supervillin slow cell spreading; SV1-171 co-localizes with mono- and di-
phosphorylated MLC and L-MLCK, but not with S-MLCK or with the MYPT1 subunit of myosin phosphatase. (A) Percentages of spread
COS7 cells transfected with EGFP (Control) or EGFP-SV: full length (SV-FL), SV1-171, SV343-571, SV570-830, SV343-830, SV171-1792.
Means±s.e.m.; n=6; ***P<0.001 versus EGFP control; **P<0.01 versus EGFP control. (B) COS7 cells transfected with EGFP-SV1-171 (SV1-
171, a,g; green in c,i) or EGFP only (Control, d; green in f) and counterstained with anti-phosphoSer19-MLC antibodies (pS19-MLC, b,e; red
in c,f) or antibody against pThr18pSer19-MLC (h; red in i). Overlap in merged images (c,f,i) appears yellow. Bar, 20 m. (C) Co-transfected
COS7 cells expressing EGFP-SV1-171 (SV1-171, a,g) or EGFP only (Control, d) and Flag-tagged L-MLCK (b,e) or S-MLCK (h) and
counterstained with Alexa-Fluor-350–phalloidin (c,f,i). Cells expressing EGFP-SV1-171 alone (j,m) were stained with antibodies against the
MYPT1 subunit of myosin phosphatase (k,n) and phosphoS19-MLC (l,o). (m-o) Enlargements of the boxed areas in j-l. Arrows show punctae
of SV1-171 with pS19-MLC that lack MYPT1. Bars, 20 m (a-l); 5 m (m-o).
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Discussion
We demonstrate here that SV decreases the rate of cell
spreading via interactions with myosin II, F-actin and L-
MLCK. SV co-localized with F-actin and myosin II filament
bundles at the plasma membrane, and SV levels correlated with
the extent of bundle formation during initial cell spreading. SV
binds directly to myosin IIA and myosin IIB and to the N-
terminus of L-MLCK, as well as to actin filaments (Chen et
al., 2003). SV-associated filament bundles are enriched in L-
MLCK and, to a lesser extent, in S-MLCK. Pharmacological
inhibition of MLCK or myosin motor activity reverses the SV-
mediated decreases in the rate of cell spreading, and MLCK
overexpression phenocopies the SV effect. Cell spreading is
slowed by L-MLCK and SV sequences that bundle F-actin.
Cell spreading is also slowed by SV1-171, which binds myosin
II and L-MLCK in vitro and co-localizes with aggregates of L-
MLCK and activated myosin II in vivo. Thus, SV apparently
modulates cell spreading by promoting or stabilizing
actomyosin bundles and/or upregulating myosin II activation
at the plasma membrane.
The major new finding reported here is that SV, a membrane
protein, enhances L-MLCK-mediated myosin II function
during cell spreading. Others have used myosin II inhibitors,
including blebbistatin, to show that myosin II plays an active
role in promoting cell spreading (Betapudi et al., 2006; Cramer
and Mitchison, 1995; Duxbury et al., 2004; Sumoza-Toledo et
al., 2006; Wakatsuki et al., 2003). Inhibition of MLCK with
high concentrations (5 M) of ML-7 slows cell spreading
(Betapudi et al., 2006; Giannone et al., 2004). We show here
that SV introduces a biphasic nature to the inhibitor dose-
response curves (Figs 7, 9) consistent with SV-mediated
enhancement of myosin II-mediated contractility that
antagonizes cell spreading. Low concentrations of either
blebbistatin (20 M) or ML-7 (1 M) alleviate the SV-
mediated effect, returning the rate of cell spreading to that
observed with lower SV levels. These results suggest that
subpopulations of myosin II and MLCK, distinguished by
myosin isoform and/or associated proteins, might be
differentially sensitive to low concentrations of these drugs
and/or to regulation by SV.
Our results also suggest that SV is part of an interconnected
membrane-associated scaffold that helps position myosin II
and F-actin with respect to MLCK. Myosin II and actin
filaments have long been known to assemble at the membrane
surface (DeBiasio et al., 1988; McKenna et al., 1989; Rhee et
al., 1994) and to interact with both L-MLCK and S-MLCK
(Blue et al., 2002; Dulyaninova et al., 2004; Poperechnaya et
al., 2000; Stull et al., 1998). The additional F-actin-binding and
-bundling sequences in the unique L-MLCK N-terminus
apparently increase the affinity of L-MLCK, relative to S-
MLCK, for actin filaments (Smith et al., 2002; Yang et al.,
2006). SV also binds to both myosin and actin filaments, with
the physical separation of the F-actin- and myosin II-binding
sites within SV consistent with its suggested potential for
regulated recruitment of actin and myosin filaments during
myofibril and stress fiber assembly at the membrane (Oh et al.,
2003).
An interaction of SV with the N-terminus of L-MLCK is
suggested by direct binding in vitro and by the preferential co-
localization of L-MLCK with SV1-171 in vivo. Simultaneous
binding of SV1-171 to myosin and to L-MLCK could provide
Journal of Cell Science 120 (21)
the basis for SV-mediated activation of myosin II by helping
to retain or position L-MLCK on the myosin II heavy chain.
An SV-associated scaffold could mediate local MLCK
activation via phosphorylation by ERK during cell spreading
(Huang et al., 2004; Klemke et al., 1997). This possibility is
consistent with the ability of the MEK inhibitor U0126 to
reverse SV-mediated effects on cell spreading (Fig. 9) and with
the co-localization of SV, myosin II and ERK in smooth muscle
cells (Gangopadhyay et al., 2004). The suggestion that ERK
signaling might be regulated by SV is also consistent with the
observation that ERK activation during agonist-mediated
contraction is inhibited by knockdown of the smooth muscle
isoform of SV in ferret aorta (Gangopadhyay et al., 2004). The
interaction between SV and calponin (Gangopadhyay et al.,
2004) – a protein that binds directly to F-actin, myosin II and
ERK (Leinweber et al., 1999; Morgan and Gangopadhyay,
2001) – suggests a further level of interconnection.
A second possible mechanism is that the binding of SV1-
171 to subfragment 2 of myosin regulates its conformation and
thus increases the affinity of L-MLCK for the myosin head-rod
junction (Masato et al., 1997). For example, SV1-171 binding
to myosin might promote myosin monomer unfolding and thus
facilitate myosin activation by MLC phosphorylation and
subsequent filament assembly (Kolega, 1998; Kolega and
Taylor, 1993). Conversely, SV might stabilize the myosin
filament or block myosin filament disassembly. For instance,
by binding to subfragment 2 of myosin, SV might block
binding of myosin phosphatase to this site (Johnson et al.,
1997; Mitsui et al., 1992), shifting the dynamic equilibrium of
dephosphorylated versus phosphorylated MLC and leading to
the observed exclusion of MYPTI and the accumulation of
mono- and di-phosphorylated MLC with SV and SV1-171
(Fig. 12).
SV might also stabilize contractile assemblies by bundling
and thus stabilizing actin filaments against disassembly. This
hypothesis is consistent with the observations that the actin-
bundling fragments of SV and L-MLCK decrease the rate of
cell spreading. This possibility is also consistent with recent
work showing that myosin II slows cell protrusion by
accelerating actin filament fragmentation in a contractile zone
away from the leading edge (Medeiros et al., 2006), a process
that is antagonized by actin filament stabilization, such as by
tropomyosin (Huckaba et al., 2006). Given the sequence
similarity between the SV C-terminus and the actin filament-
severing proteins villin and gelsolin (Pestonjamasp et al.,
1997), SV-mediated filament stabilization might seem unlikely.
However, sequences required for F-actin severing in gelsolin
and villin (Matsudaira et al., 1985) are absent from SV
(Pestonjamasp et al., 1997; Wulfkuhle et al., 1999).
Another possibility is that the combined F-actin and myosin
II binding capabilities of SV regulate the actomyosin cross-
bridge cycle in the way proposed for calponin and caldesmon
(Szymanski, 2004). Smooth muscle isoforms of these proteins
are thought to act as ‘latch bridges’ that inhibit myosin cross-
bridge cycling while binding to both F-actin and activated
myosin II, stabilizing the contractile state. In this model, SV1-
171 competes for binding on myosin subfragment 2 with
endogenous full-length SV and/or nonmuscle caldesmon,
releasing the latch state and inducing the localized contractions
that apparently destabilize stress fiber integrity (supplementary
material Movie 3).
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These possible modes of action are not mutually exclusive
because SV regulation of actin-myosin interactions at the
membrane might differ with intracellular location. For
instance, SV might promote myosin activation in the posited
signaling scaffold with L-MLCK at the cell periphery
(Medeiros et al., 2006) and inhibit myosin II function
elsewhere. SV1-171 and SV343-571 both reduce the number
of large focal adhesions in the center of the cell (Takizawa et
al., 2006). The effect of SV1-171 is consistent with a role for
SV in potentiating L-MLCK-induced focal adhesion
disassembly at various intracellular sites (Webb et al., 2004),
but the lack of effect of SV343-571 on cell spreading (Fig. 12)
argues strongly for a second regulatory mechanism. In fact,
SV343-571 decreases cell-substrate adhesion via an interaction
with the focal adhesion protein TRIP6, which leads to loss of
stress fibers and of mature focal adhesions in the cell interior
(Takizawa et al., 2006). Thus, SV apparently participates in at
least two regulated interactions involving myosin II, F-actin
and focal adhesion proteins at different intracellular locations
during different stages of cell migration.
Materials and Methods
Chemicals
Glutathione-Sepharose was purchased from Amersham Biosciences (Piscataway,
NJ). ML-7 was from Calbiochem-Novabiochem (La Jolla, CA). Blebbistatin with
a ± stereochemical ratio of 1:1 was from Tocris (Bristol, UK). U0126 was from
Sigma (St Louis, MO). Y-27632 was from Yoshitomi Pharmaceutical Industries
(Osaka, Japan). Other chemicals were from Sigma, Calbiochem-Novabiochem,
Fisher (Pittsburgh, PA) or VWR International (Bristol, CT).
Antibodies
Rabbit polyclonal anti-nonmuscle MHC IIA, rabbit polyclonal anti-nonmuscle
MHC IIB, sheep polyclonal anti-MLCK and rabbit polyclonal anti-MYPT1 were
from BAbco-Covance (Richmond, CA). Rabbit polyclonal anti-ERK1/2 was from
Upstate (Lake Placid, NY). Mouse monoclonal anti--tubulin (TUB2.1), mouse
monoclonal vinculin (hVIN1) and rabbit polyclonal anti-Flag were from Sigma.
Mouse monoclonal anti-phospho-Ser19 MLC, rabbit polyclonal anti-phospho-
Thr18/Ser19 MLC and mouse monoclonal anti-6His (27E8) were from Cell
Signaling Technology (Beverly, MA). Goat polyclonal anti-GST antibodies were
from Amersham. Horseradish peroxidase (HRP)-conjugated secondary antibodies
against rabbit, mouse and goat/sheep IgGs were from Jackson ImmunoResearch
(West Grove, PA). Rabbit polyclonal anti-SV (H340) has been described (Nebl et
al., 2002; Oh et al., 2003).
Mammalian expression vectors
EGFP-SV and EGFP-SV fragment vectors were described previously (Chen et al.,
2003; Wulfkuhle et al., 1999). EGFP-SV171-1792 was made by ligating the
fragment released from EGFP-SV171-571 with AgeI into AgeI-digested EGFP-SV
(Chen et al., 2003). Plasmids encoding Flag-tagged wild-type and KD murine 220
kDa L-MLCK and Flag-tagged rabbit 130 kDa S-MLCK were gifts from Patricia
Gallagher (Indiana University School of Medicine, IN) (Blue et al., 2002).
Constructs encoding EGFP-tagged N-terminal fragments of human L-MLCK
(amino acids 2-867 and 2-1024) and EGFP-tagged rabbit five DXR actin-binding
domains (Smith et al., 2002) were provided by Anne R. Bresnick (Albert Einstein
College of Medicine, Bronx, NY) (Dulyaninova et al., 2004).
Recombinant proteins
GST tagged SV1-174 was described previously (Chen et al., 2003). The S2 domains
of human nonmuscle myosin IIA (NP002464, coding amino acid sequences 837-
1188, LLQVSRQ-THEAQIQ), human nonmuscle myosin IIB (NP005955, coding
amino acid sequences 844-1192, LLQVTRQ-ETKNHEA) and human skeletal
muscle myosin II (NP005954, coding amino acid sequences 843-1246, LLKSAET-
ETVSKAK) were subcloned into the pFastBac1 vector (Invitrogen, Carlsbad, CA)
with a C-terminal hexa-histidine (6His) tag. The Ig and five DXR domains from
L-MLCK were expressed with N-terminal 6His tags using the pet30a vector
(Novagen). 6His-tagged myosin II S2 domains and MLCK proteins were
expressed in Sf9 cells and BL21(DE3)LysS, respectively, and purified with
Ni2+NTA agarose columns (Qiagen, Valencia, CA), according to the manufacturer’s
protocol.
Cell culture and transfection
COS7-2 cells, a highly transfectable clone of COS7 (Kowalczyk et al., 1997), were
a generous gift from Kathleen J. Green (Northwestern University, IL). COS7-2 cells
were grown in Dulbecco’s Modified Eagle high glucose media (DME)
supplemented with 10% fetal calf serum (FCS) for 20 passages. A549 human non-
small cell lung carcinoma cells [American Type Culture Collection (ATCC),
Rockville, MD] were maintained in Ham’s F12K medium, 2 mM L-glutamine, 10%
FCS for up to 12 passages.
Transfection methods have been described (Takizawa et al., 2006). Briefly, COS7
cells were transfected using Effectene Transfection Reagent (Qiagen) for 24 hours,
except in experiments with L-MLCK N-terminal sequences, which were lethal to
cells transfected for longer than 16 hours (Dulyaninova et al., 2004). A549 cells at
~60% confluence were transfected twice with 10 nM dsRNA and Lipofectamine
2000, as recommended (Invitrogen), and grown for 4 days. Two dsRNAs targeting
human SV were made as Stealth duplexes (Invitrogen): human (h)SV1, 5-
CAGCCAUAAGGAAUCUAAAUAUGCU-3 (coding nucleotides 1680-1704) and
hSV2, 5-GCGAUGUUUGCUGCUGGAGAGAUCA-3 (coding nucleotides 2026-
2050). The Stealth duplex sequence, 5-GAACUAUGAAGGACCACCAGAGAUA-
3, was used as a control dsRNA. Cell growth was similar for mock and dsRNAi-
treated cells (data not shown).
Cell-spreading assay
Cells were cultured in T25 tissue culture flasks (25 cm2) and detached by incubating
at 37°C for 2 minutes with 0.5 ml trypsin/EDTA solution (0.1%/0.40 mg/ml for
COS7 cells, or 0.25%/1.0 mg/ml for A549 cells). Trypsin was immediately
neutralized with 5 ml culture medium containing 5 g/ml aprotinin, and the cells
were washed once with 10 ml PBS, pH 7.2-7.4. Cells were adjusted to 3.0104
cells/ml of serum- and antibiotic-free media (2.5 ml/well for COS7 cells, or 2.0
ml/well for A549 cells), and were transferred into wells (9.60 cm2) of six-well plates
containing 1818 mm coverslips coated with 10 g/ml bovine plasma fibronectin
(Sigma). For experiments with chemical inhibitors, 2 concentrations of cells were
added to wells containing equal amounts of media with 2 concentrations of
inhibitors. At each time point, cells were fixed with 4% paraformaldehyde and
counted using a 40 Pan-NeoFluor oil immersion objective (NA 1.3) with phase-
contrast optics on a Zeiss Axioskop microscope (Carl Zeiss MicroImaging,
Thornwood, NY).
Immunofluorescence microscopy
Methods for indirect immunofluorescence microscopy have been described
previously (Chen et al., 2003; Takizawa et al., 2006). Briefly, cells were fixed for
20 minutes with 4% paraformaldehyde in PBS, 1 mM MgCl2, 1 mM EGTA and
permeabilized for 5 minutes with 0.1% Triton X-100, PBS before immunostaining.
Depending on the experiment, cells were stained for nonmuscle MHC IIA (1:400
dilution), MHC IIB (1:400), -tubulin (1:400), vinculin (1:200), phospho-Ser19
MLC (1:200), phospho-Thr18/Ser19 MLC (1:200), MYPT1 (1:100), Flag (1:100),
and/or SV (1:100). Cross-adsorbed secondary antibodies, conjugated with Alexa-
Fluor-350, -488, or -594 were from Invitrogen Molecular Probes (Eugene, OR). F-
actin was visualized with phalloidin conjugated to Texas-Red or Alexa-Fluor-350
(Molecular Probes). Slides were analyzed with a 100 Pan-NeoFluar oil immersion
objective (NA 1.3) on a Zeiss Axioskop fluorescence microscope with a RETIGA
1300 CCD camera (QImaging Corp., Burnsby BC, Canada) and OpenLab software
(Improvision, Lexington, MA). Each channel of the epifluorescence micrographs
was scaled automatically using the Auto Level submenu in Adobe Photoshop 7.0
(San Jose, CA). Due to the high background in Alexa-Fluor-350–phalloidin images
(Figs 3, 6, 8, 10, 12; supplementary material Figs S2, S3, S4), background was
subtracted after Auto Level manipulation. This operation might also remove weak
Alexa-Fluor-350 signals. Image intensity profiles were obtained using the Plot
Profile subprogram in ImageJ 1.37v (NIH, Bethesda, MD).
Live-cell imaging
dsRNA-transfected A549 cells were allowed to settle onto fibronectin (10 g/ml)-
coated 35 mm chambers (FluoroDish, World Precision Instruments, Sarasota, FL)
containing 3 ml DME without phenol red on a DMIRE 2 inverted microscope (Leica
Microsystems, Allendale, NJ) in a Plexiglass environmental chamber heated to
37°C. Phase contrast images of the chamber surface were acquired with an HC PL
Ph2, 20, 0.50 NA, air objective lens and a Retiga Exi cooled CCD camera
(QImaging), using Open Lab 3.5.2 software (Movies 1, 2). EGFP-SV1-171-
transfected COS7 cells on square coverslips (22 mm) in a chamber containing DME
+ 10% FCS without phenol red were visualized similarly using an HCX PL Apo,
63, 1.32 NA, oil immersion objective lens (Movie 3). Images were processed with
OpenLab to generate movie files.
L-MLCK- and myosin-binding assays
Binding assays with myosin II S2 domains have been described (Chen et al., 2003).
Briefly, 6His-tagged myosin S2 domains (100 g) were incubated for 1 hour at
4°C with glutathione-Sepharose (50 l) containing pre-bound GST-SV1-174 or
GST (100 g) proteins in binding buffer (10 mM MOPS, pH 7.5, 1 mM ATP, 5
mM MgCl2, 50 mM NaCl, 0.05% -mercaptoethanol). Beads were transferred to a
2 ml column, and the columns were washed with 0.5 ml of binding buffer and then
with 100-l portions of binding buffer containing increasing concentrations (0.1,
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0.15, 0.2 and 0.3 M) of NaCl. Binding assays with L-MLCK fragments (100 g)
were performed similarly, except that the binding buffer was 10 mM MOPS, 100
mM imidazole, pH 7.5, 100 mM KCl, 50 M EGTA, 0.05% -mercaptoethanol,
3.25% glycerol, and the column was washed with 0.25 ml portions of a buffer
containing 20 mM MOPS, 20 mM imidazole, pH 7.5, 0.1 mM EGTA, 0.1% -
mercaptoethanol with increasing concentrations (0.1, 0.1, 0.15, 0.2 and 0.3 M) of
NaCl. GST proteins and bound myosin or L-MLCK fragments were eluted from the
washed columns with 250 l of 5 mM glutathione in washing buffer with 0.3 M
NaCl. Fractionated proteins were analyzed by immunoblot analysis using anti-GST
antibodies (goat polyclonal; 1:1000; Amersham) and anti-6His antibodies (mouse
clone 27E8; 1:1000).
Immunoblotting and SDS-PAGE
SDS-PAGE and immunoblotting have been described (Takizawa et al., 2006).
Primary antibodies and dilutions: anti-SV (H340), 1:10,000; anti-MHC IIA,
1:10,000; anti-MHC IIB, 1:10,000; anti-MLCK, 1:3000; anti-ERK1/2, 1:3000; anti-
GST, 1:1000; and 6His, 1:1000. HRP-conjugated secondary antibodies and
dilutions: anti-rabbit IgG, 1:10,000; anti-mouse IgG, 1:10,000; anti-goat/sheep IgG;
1:10,000.
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